U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H3F7O
Molecular Weight 200.0548
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SEVOFLURANE

SMILES

FCOC(C(F)(F)F)C(F)(F)F

InChI

InChIKey=DFEYYRMXOJXZRJ-UHFFFAOYSA-N
InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

HIDE SMILES / InChI

Molecular Formula C4H3F7O
Molecular Weight 200.0548
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Sevoflurane is a general anesthetic that is FDA approved for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor. Common adverse reactions include cardiovascular: bradyarrhythmia, hypotension, gastrointestinal: nausea, vomiting, neurologic: somnolence, psychiatric: agitation, respiratory: cough, interrupted breathing and other: shivering.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.5 mM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ULTANE

Cmax

ValueDoseCo-administeredAnalytePopulation
25.6 μM
1.7 % single, respiratory
FLUORIDE ION plasma
Homo sapiens
26.1 μM
2.1 % single, respiratory
FLUORIDE ION plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
1.7 % single, respiratory
FLUORIDE ION plasma
Homo sapiens
33 h
2.1 % single, respiratory
FLUORIDE ION plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide.
Route of Administration: Respiratory
In Vitro Use Guide
Currents elicited by GABA 0.01 mM were increased by low sevoflurane concentrations to 183% and decreased by high sevoflurane concentrations (> 1 mM) to 34% (P < 0.05). Ten- to 90%-rise times of the currents were reduced by sevoflurane concentration dependently. At GABA (1 mM), peak currents and 10-90%-rise times decreased with increasing sevoflurane concentrations.
Substance Class Chemical
Record UNII
38LVP0K73A
Record Status Validated (UNII)
Record Version